ATORX — Alligator Bioscience AB Share News
0.000.00%
Last trade - 00:00- SEK89.83m
- SEK103.14m
- SEK0.51m
Brief: Alligator Bioscience Announces Positive Mitazalimab Optimize-1 Phase 2 Results
Brief: Alligator Bioscience Gets Granted U.S. Patent For Cancer Treatment Antibody
Brief: Alligator Bioscience Q3 Operating Result Turns To Loss of SEK 52.7 Mln
Brief: Alligator Gets About SEK 13.8 Million Through Exercise Of Warrants
Brief: Alligator Bioscience Receives EMA Orphan Designation For Mitazalimab
Brief: Alligator Bioscience Q2 EBIT Loss at SEK 63.7 Million
Brief: Alligator Bioscience: Positive 2nd Interim Efficacy Analysis From Mitazalimab Optimize-1 Phase 2 Study In 1st Line Pancreatic Cancer
Brief: Alligator Bioscience, Orion Corporation Announce Exercise Of Development Option
Brief: Alligator Bioscience Posts Q1 Net Loss of SEK 62.5 Million
Brief: Alligator Bioscience Gets FDA Authorization To Start Mitazalimab Optimize-2 Phase 2 Trial
Brief: Alligator Intends To Carry Out Rights Issue Of Units Of About SEK 199 Mln
Brief: Alligator Bioscience Q4 Oper Loss Widens To SEK 52.6 Mln
Brief: Alligator Bioscience Announces Positive Interim Results From Phase 2 Trial
Brief: Alligator Bioscience And Orion Corporation Initiate Second Program Of Immuno-Oncology Research Collaboration And License Agreement
Brief: Alligator Bioscience: Data Confirm Mitazalimab's Manageable Safety Profile
Brief: Alligator Bioscience Q3 Oper Loss Widens To SEK 51.4 Mln
Brief: Alligator Bioscience Announces Positive Safety Data
Brief: Alligator Bioscience, Aptevo Therapeutics Announce FDA Issues "May Proceed" Notification
Brief: Alligator Bioscience Q2 Loss Widens To SEK 45.7 Million